Stock Market Reviews

IDYA (IDEAYA Biosciences, Inc.) News

Get the latest news, insights, and market updates on IDYA (IDEAYA Biosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
  IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
  Oct 27, 2025 - $IDYA
• What IDEAYA Biosciences (IDYA)'s Strong Uveal Melanoma Data Means for Shareholders
  IDEAYA Biosciences recently presented positive Phase 2 clinical data at ESMO 2025, showing darovasertib achieved robust tumor shrinkage and eye preservation in patients with primary uveal melanoma, a cancer with no currently approved systemic therapies. The data not only highlighted significant vision and eye-saving benefits, but also paved the way for an ongoing Phase 3 trial and potential accelerated U.S. regulatory submission. We’ll examine how the impressive eye and vision preservation...
  Oct 23, 2025 - $IDYA
• IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
  IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today presented positive clinical data from their ongoing Phase 2 OptimUM-09 trial of neoadjuvant darovasertib in patients with primary uveal melanoma (UM). The data were presented in a Proffered Paper oral presentation by Dr. Marcus Butler, M.D., Associate Professor, Princess Margaret Cancer Center at the University of Toronto, at the 2025 European Society of Medical Oncology (ESMO) in Berlin, Germany. There
  Oct 20, 2025 - $IDYA
• Citizens JMP Remains Bullish on IDEAYA Biosciences (IDYA)
  IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best healthcare stocks with the highest upside. Citizens JMP analyst Silvan Tuerkcan released a rating update for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) on October 13, maintaining a Buy rating for the stock with a price target of $45. IDEAYA Biosciences, Inc. (NASDAQ:IDYA) also received a bullish rating from J.P. […]
  Oct 18, 2025 - $IDYA
• J.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA)
  IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best biotech stocks with high potential. On September 23, J.P. Morgan analyst Anupam Rama maintained a bullish stance on IDEAYA Biosciences, Inc. (NASDAQ:IDYA), giving the stock a Buy rating with a $74 price target. The analyst based the rating on several promising developments associated with the company’s […]
  Oct 8, 2025 - $IDYA
• Could IDEAYA Biosciences' (IDYA) Expanding Pipeline Redefine Its Long-Term Value Proposition?
  IDEAYA Biosciences recently presented encouraging interim clinical results from multiple pipeline programs, including IDE397 for MTAP-deletion urothelial cancer, darovasertib in neoadjuvant uveal melanoma, and IDE849 for solid tumors, at its 10-Year Anniversary R&D Day in New York. These updates provided early signs of efficacy across several programs, particularly in understudied patient populations with few approved treatment options. We'll explore how IDEAYA's favorable data in...
  Sep 13, 2025 - $IDYA
• Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating
  IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 4, Citizens JMP analyst Ivan Tuerkcan initiated coverage of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) with a $41 price target. The firm started coverage of the company after it announced enrolling the first patient […]
  Sep 10, 2025 - $IDYA
• Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Rate-Cut Hopes, Soft Data
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad
  Sep 8, 2025 - $IDYA
• Ideaya Biosciences Says Darovasertib Data Show Tumor Shrinkage in Phase 2 Eye Cancer Trial
  Ideaya Biosciences (IDYA) said Monday that interim phase 2 data for darovasertib in the neoadjuvant
  Sep 8, 2025 - $IDYA
• IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
  IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, will present initial data at their 10-Year Anniversary R&D Day from two expansion cohorts in their Phase 1/2 combination trial of IDE397, a potential first-in-class, small molecule adenosyltransferase 2a (MAT2A) inhibitor, in combination with Gilead's Trodelvy® (sacituzumab govitecan-hziy), a Trop2-directed antibody-drug conjugate (ADC), in patients with late-line methylthioadenosine phosphorylase (MTAP)-dele
  Sep 8, 2025 - $IDYA